Search

everythinglearnresearchcommunity

for

Search:↓

A user is seeking a recipe to create a topical solution using Minoxidil tablets, rosemary, peppermint, and possibly coconut oil. They are asking for specific amounts and mixing instructions.

The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.

RU-58841 does not dissolve well in common Minoxidil solutions due to water content, requiring a 70/30 ethanol/propylene glycol mix. Users report using separate solutions for RU-58841 and finasteride/Minoxidil for better results.

Breezula may be released around 2027 but its effectiveness for advanced thinning is uncertain, and it might be expensive. Users discuss alternatives like low-dose topical finasteride and combining it with Breezula for better results.

Avoid home-compounding topical minoxidil due to potential risks and complications. Use proper equipment and techniques to prevent aerosolization and ensure effective dissolution.

A 28-year-old male shares progress using 5mg Minoxidil and 0.5mg Dutasteride for hair growth, encouraging the use of these treatments. Users discuss side effects like increased facial hair and debate the effectiveness of treatments within three months.

A humorous discussion about hair loss treatments, specifically mentioning the use of 5mg of Dutasteride. The conversation includes jokes about the effectiveness of the treatment.

A satirical discussion on using minoxidil and finasteride in unconventional ways, including mixing them into drinks and other humorous methods. The conversation also touches on the potential health risks of minoxidil.

The user is seeking a topical minoxidil and finasteride combination without propylene glycol due to scalp irritation. They are looking for a supplier in the US.

The user is considering adding an anti-androgen, RU58841, to their current hair loss treatment routine due to receding hair. They are also contemplating waiting for Breezula or Pyrilutamide to become more affordable.

The conversation is about a person considering making their own topical finasteride to avoid side effects from oral use. They discuss potential methods and ingredients, including cayenne pepper extract, rosemary, and coconut oil, and seek advice on effectiveness and alternatives like light therapy or dermarolling.

The conversation is about the effectiveness of 0.25% topical finasteride compared to other concentrations and forms. Users discuss its potential for better scalp DHT reduction and fewer side effects, with some preferring topical over oral treatments.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.

The user is dissatisfied with the results of using 0.3% finasteride and 6% minoxidil for hair thinning and is considering a topical treatment combining finasteride, dutasteride, minoxidil, melatonin, caffeine, and latanoprost. Another user suggests that high topical concentrations can lead to systemic exposure and recommends using oral dutasteride and microdosing topical finasteride.

The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.

Latanoprost is discussed as a potential hair loss treatment, noted for its synergy with minoxidil and 5-AR inhibitors, but concerns include its effectiveness on scalp hair, cost, and potential skin darkening. Some users express interest in trying latanoprost or bimatoprost despite limited real-world evidence.

A 31-year-old Indian male has been using oral minoxidil and finasteride for hair loss without visible improvement. He is considering taking DUT tablets against his doctor's advice due to potential side effects and is contemplating buzzing his hair instead.

A 26-year-old is considering switching from a finasteride and minoxidil blend to using dutasteride and minoxidil separately, with concerns about shedding and dosage changes. They are exploring options for sourcing and considering using ketoconazole shampoo to manage dryness.

The conversation discusses hair loss treatments, with users mentioning dutasteride (Dut) as effective and wishing for more accessible dosages. They also debate the components of the "big 3" treatments, which now include Dut, RU58841, and oral minoxidil, with finasteride and minoxidil being consistently mentioned.

The conversation is about improving castor oil absorption for hair loss treatment. The user tried ethanol and sweet almond oil mixtures and plans to try DMSO next.

A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.

PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

The user is experiencing a burning sensation on their scalp despite using finasteride and nizoral for hair loss, and is unsure if they should switch to dutasteride. They have reduced their testosterone dose but the burning persists, and a trichologist suggested it might be telogen effluvium.